‘Killed it on the spot': Infant bites cobra to death after it coiled around his hands
The one-year-old boy, identified only by his first name Govinda, bit the cobra while he was playing at his home in the small town of Bettiah near the Indo-Nepal border, according to local news reports.
"When we saw the snake in the child's hand, everyone rushed towards him, but in the meantime, he already bit the snake, killing it on the spot," the child's grandmother told local news.
After biting the snake, the boy fainted and was rushed to a primary health care centre for initial treatment, after which he was taken to the town's Government Medical College Hospital (GMCH).
'The boy, Govind Kumar, was referred here yesterday by the primary health centre close to his village where he was rushed by family members after he fainted soon after chewing on the live snake,' hospital superintendent Duvakant Mishra told Indian Express.
The venom's effects were reportedly mild, only knocking the boy unconscious, but not fatal.
"Timely treatment saved Govinda's life," Saurabh Kumar, a doctor of the government hospital, told the Times of India.
"The child's condition is currently stable and treatment is being administered under the supervision of doctors. The medical team is treating the child, providing continuous medication, and he is under observation,' Dr Kumar said.
Govinda reportedly is being closely monitored at GMCH Bettiah with treatment for poisoning expected to start if he started showing any symptoms, according to local news reports.
India has around 300 species of snakes, including 60 highly venomous snakes such as the Russell's vipers, kraits, and the saw-scaled viper, which are responsible for most of the bite-related deaths.
The Indian cobra completes this list of the "big four" species responsible for the most snakebites in India.
The country recorded over a million snake bite deaths in just two decades from 2000-19, according to a study published in 2020 in the journal eLife.
More than two-thirds of the recorded deaths came from eight of India's 28 states, including Bihar, Jharkhand, Madhya Pradesh, Odisha and Uttar Pradesh.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
8 hours ago
- Entrepreneur
Quadria Group Appoints Namit Chugh as Director to Strengthen Health-tech Investment Focus
You're reading Entrepreneur India, an international franchise of Entrepreneur Media. HealthQuad, the healthcare-focused growth venture capital platform of Quadria Group, has appointed Namit Chugh as Director, marking a strategic move to bolster its investment approach in deep-tech and tech-enabled healthcare models. Chugh brings over 15 years of experience in healthtech investing and consulting. Welcoming the appointment, Dr Amit Varma, Co-founder of HealthQuad, said, "We are excited to welcome Namit to the HealthQuad team. His ability to identify and scale early-stage ventures with real-world healthcare impact aligns strongly with our mission. Namit brings fresh perspectives, deep sector insight, and a sharp founder-first mindset, qualities that will further strengthen our approach to identifying and nurturing the next wave of healthcare disruptors in India." Before joining HealthQuad, Chugh was Principal at W Health Ventures, an early-stage healthtech fund where he was part of the founding team. He played a central role in shaping the India and India–US corridor investment strategy, leading investments in companies such as Wysa, BeatO, and Mylo. He was also involved in the creation of 2070 Health, the venture studio arm of W Health Ventures, supporting tech-enabled companies at the seed stage and establishing India's only seed-to-venture healthtech platform. Earlier in his career, Chugh worked with Lok Capital, where he executed and exited investments across healthcare, consumer-tech, and insurtech, including Dr Mohan's Diabetes Center and Renewbuy. He also held roles at consulting firms Alvarez & Marsal and PwC, focusing on healthcare strategy and transaction advisory. At HealthQuad, Chugh will be responsible for identifying high-impact growth venture opportunities in areas such as artificial intelligence and other advanced technologies in healthcare, strengthening founder engagement, and driving thematic investment strategies. His appointment comes as HealthQuad expands its focus in high-growth sectors including healthtech, medtech, biopharma, and digitally enabled care. The expansion is supported by the recently launched HealthQuad Fund III, targeting up to USD 200 million with an additional USD 100 million option. Sunil Thakur, Co-founder of HealthQuad, noted, "Namit's track record of backing differentiated healthcare startups, combined with his operational rigor and ecosystem understanding, makes him a strong strategic addition to our leadership. His experience in cross-border models and thematic innovation will complement our vision as we double down on backing category-defining ventures in India and beyond." Reflecting on his new role, Chugh said, "Joining HealthQuad at this exciting phase is a natural next step in my journey of backing meaningful healthcare innovation. The team's conviction in supporting companies solving India's critical healthcare challenges resonates deeply with my own. I look forward to contributing towards building scalable, tech-enabled, and impactful healthcare models that improve access and outcomes for millions."
Bloomberg
10 hours ago
- Bloomberg
Venus Williams Exposed All That's Wrong With Health Insurance
Venus Williams returned to the professional tennis circuit in July with a win in the first round of the DC Open. (She lost in a late round.) In an interview on the court following the match, the 45-year-old made a somewhat surprising admission on why she decided to return to competitive tennis. 'I had to come back for the insurance because they informed me earlier this year I'm on COBRA," she said, referring to the federal law that allows individuals to temporarily continue their employer-sponsored health insurance after leaving a job by paying the premiums. Williams has made more than $40 million in prize money during her tennis career and has a net worth estimated to be almost $100 million. There's little worry she'd become uninsured due to lack of funds. Still, her comments get at the problem buried so deep into our system of health insurance that no policymaker has the nerve to touch it, which is that health and work shouldn't be linked.
Yahoo
20 hours ago
- Yahoo
Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics
Shilpa Medicare Serves as Lead Investor, Positioning Alveolus Bio for Phase 2 Clinical Trials and First-in-Human Studies CAMBRIDGE, Mass. and BIRMINGHAM, Ala. and RAICHUR, India, Aug. 4, 2025 /PRNewswire/ -- Alveolus Bio, a pioneering respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, AL, has announced a strategic financing round led by Shilpa Medicare Limited (BSE: 524742) (NSE: SHILPAMED), a prominent global pharmaceutical company with extensive expertise in respiratory therapeutics manufacturing and biotechnology innovation. Through this collaboration, Shilpa Biologics, the biologics arm of Shilpa Medicare, will become Alveolus Bio's exclusive global development and manufacturing partner. This partnership propels Alveolus Bio's live biotherapeutics and small molecule platform towards Phase 2 and first-in-human clinical trials, with a lead asset for COPD progressing rapidly. Shilpa Medicare brings deep experience in drug discovery, development, and manufacturing, along with strong regulatory capabilities. Their investment and strategic involvement will accelerate the clinical advancement of Alveolus Bio's resMIT (respiratory microbiota-based inhaled therapeutics) platform. This novel platform enables targeted delivery of inhaled therapies to deep lung regions, addressing unmet needs in diseases such as COPD, Bronchopulmonary Dysplasia (BPD), and Pulmonary Fibrosis. "Securing Shilpa as our lead investor is a transformative step," said Gaurav Mehta, CEO of Alveolus Bio. "Their global pharmaceutical leadership aligns perfectly with our vision to redefine how lung diseases are treated." "Alveolus Bio's breakthrough science is poised to transform respiratory care. Through this strategic partnership with Shilpa, we combine disruptive biotech innovation with world-class commercialization, bringing life-changing therapies faster to the market," said Dr. C. Vivek Lal, Founder and CSO, Alveolus Bio. "Shilpa has always focused on enabling breakthrough biologics," said Vishnukant Bhutada, Managing Director, Shilpa Medicare. "This partnership strengthens our innovation pipeline and reinforces our role as a trusted global partner for biotech development." The financing round remains open to other strategic investors who share Alveolus Bio's vision of transforming respiratory medicine. About Shilpa MedicareShilpa Medicare is a global pharmaceutical company with capabilities across drug discovery to commercialization, specializing in respiratory therapeutics and biotech innovation. Visit About Alveolus BioA Biostack Ventures company, Alveolus Bio is developing first-in-class therapies for lung diseases using its proprietary resMIT platform. Its pipeline includes programs for COPD, BPD, Pulmonary Fibrosis, Cystic Fibrosis, and more. View original content: SOURCE Shilpa Medicare Limited Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
